---
title: 'Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia
  or Lymphoblastic Lymphoma: DELPHINUS Study'
date: '2024-08-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39158071/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240819180915&v=2.18.0.post9+e462414
source: Blood
description: Patients with relapsed/refractory acute lymphoblastic leukemia (ALL)
  or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed,
  treatment-naïve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab
  (16 mg/kg intravenously) plus backbone chemotherapy in children with relapsed/refractory
  B-cell ALL (n=7) after ≥2 relapses and children and young adults with T-cell ALL
  (children, n=24; young adults, n=5) or LL (n=10) after first relapse. The primary
  ...
disable_comments: true
---
Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed, treatment-naïve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab (16 mg/kg intravenously) plus backbone chemotherapy in children with relapsed/refractory B-cell ALL (n=7) after ≥2 relapses and children and young adults with T-cell ALL (children, n=24; young adults, n=5) or LL (n=10) after first relapse. The primary ...